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EDITORIAL

Intensive Care Unit Renal Replacement Therapy:
Less Is More (or Better)

A

cute kidney injury (AKI) is on every nephrologist’s
mind. Although it took some time for the transition
to the nomenclature of CKD stages from chronic kidney
failure, the rapid assimilation of “AKI” into the internal
medicine vernacular has been relatively light speed.
Now, AKI must be considered a cause of CKD, although
not necessarily in the fashion of a 5/6 nephrectomy—an
immediate cause of CKD that is accompanied by a tremendous degree of compensatory hypertrophy unseen in the
human analogue. In a retrospective analysis of hospitalized veterans by Heung and colleagues,1 AKI that is not
of prerenal origin was associated with residual kidney
damage and CKD, deﬁned as CKD Stage 3 or greater 1year postdischarge. The individuals who recovered more
quickly, with recovery deﬁned as a predischarge serum
creatinine within 0.3 mg/dL of the baseline serum creatinine, demonstrated improved outcomes. Older patients
fared less well, as expected, which is clinically relevant
given that the elderly population is an increasingly larger
proportion of intensive care unit admissions. Bagshaw
et al.2 calculate that the rate of adults aged 80 years and
older admitted to intensive care units will increase by
72% by 2015, equaling nearly one-quarter of such admissions.
In this issue of “Advances in Chronic Kidney Disease”,
our Associate Editor, Kathleen Liu serving as guest editor
with her colleague, Michael Connor, brings forth a series
of newer ideas that the nephrologist–intensivist can use
to improve the care of critically ill individuals with AKI.
Undoubtedly, some of the concepts and innovations
described by her talented group of authors will be
embraced and used by not only today’s current nephrologists but also by the future nephrologists currently in
training. In brief, we can do more for our AKI patients
by doing more. However, we can also accomplish more
by doing less.
With the advent of continuous renal replacement
therapies, the dose of dialysis administered to ICU patients has increased. Now, there is the concept of “renal
support therapy” vs renal replacement therapy (RRT),
that is, nephrologists assist the intensivist by conducting

ultraﬁltration and/or dialysis far more than previously.3
Historically, due to the lack of an ultraﬁltration meter situated on the dialysis machine, transmembrane pressures
were calculated, usually by the dialysis nurse, to approximate the total ultraﬁltration. This estimation proved sufﬁcient in most circumstances, but was supplanted by
technology that permitted one to “dial in” ultraﬁltration
rates and volumes. Consequently, nephrologists are able
to remove large volumes of ultraﬁltrate, thereby avoiding
“ﬂuid overload (FO),” a term that implies pathophysiological distinction from heart failure with pulmonary
edema, although it is not. Avoiding FO of 10% or greater
is an evidence-based target as excessive ﬂuid administration is associated with higher mortality and greater ventilator days and ICU length of stays.4,5 This was established
much earlier than appreciated by Mitchell and colleagues6
nearly a quarter-decade ago in a randomized, prospective
study.
Nonetheless, the ability of physicians to overload a patient with ﬂuid to greater than 10% of admission weight
with a panoply of salt-containing solutions remains unfettered. First, the solution for ﬂuid resuscitation makes little
difference clinically, but it does monetarily. Saline has not
been proven inferior to either buffered saline solutions or
more expensive oncotic solutions of albumin, although
the jury is still out on this. However, excessive volume administrations of saline can obfuscate a diagnosis of AKI by
dilution and induce a hyperchloremic metabolic acidosis.
The electronic health records of patients maintain ﬂuid
logs that are easily graphed and reported, but no warning
system exists when the 10% FO threshold is reached and
subsequently surpassed, at which time the nephrologist
is consulted for renal replacement and/or support therapy.
More easily, a limitation on intravenous and other routes
of ﬂuid administration should have been imposed. When
hemodynamic resuscitation is an ongoing requirement,
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augmenting vasopressor support vs increasing ﬂuids is
the better choice because more ﬂuids foster more renal
support therapy, which devolves into a never-ending cycle. The ongoing ﬂuid administration promotes more
continuous renal replacement therapy (CRRT), either
long-term dialysis with sustained low-efﬁciency daily
dialysis or continuous venovenous hemoﬁltration
(CVVH), with or without hemodialysis (CVVHD). This
ﬂuid overloading process can be stopped by “early
goal–directed thinking,” which constitutes establishing
an FO threshold target of 10% and developing electronic
warning systems that facilitate reduction of ﬂuid administration. Notably, no ﬂuid-logging system of any electronic
health record distinguishes between the electrolytecontaining and electrolyte-free proportions of a solution.
This coalescence of ﬂuids into a single ﬂuid on a ﬂow
sheet consequently generates errant estimates of the volume of ﬂuid that should undergo ultraﬁltration, that is,
only the isotonic volume of ﬂuid should undergo ultraﬁltration, with residual tonicity problems evaluated and
managed separately.
Prolonged RRT has been misused and has its disadvantages. High-efﬂuent volume removal (35 mL/kg/h) was accorded primacy by devotees of CRRT, as this would
promote cytokine removal and potentially mitigate
inﬂammation during sepsis-induced AKI. Sustaining
such an efﬂuent rate is a formidable task and requires
time, effort, and vigilance. With the beneﬁt of data from
2 large, multicenter, randomized, controlled trials, a lesser
efﬂuent dose is recommended.7,8 The results of the
Veterans Affairs/National Institutes of Health Acute
Renal Failure Trial Network (ATN; n ¼ 1124) study7 and
the Randomized Evaluation of Normal vs Augmented
Level (n ¼ 1508) Replacement Therapy Study8 have
yielded level 1 evidence that efﬂuent ﬂow rates above
25 mL/kg/h do not provide better outcomes in patients
in the ICU. The provision of higher efﬂuent rates for
improved outcomes in sepsis-induced AKI vis-a-vis cytokine removal also remains unproven,9 and further
research into cytokine adsorption during RRT or in isolation is required.10
The KDIGO recommendation for more conventional hemoﬁltration rates of 20 to 25 mL/kg/h9 is fortunate
because it precludes in part the ongoing potassium, magnesium, and phosphate losses that occur with prolonged
hemoﬁltration or dialysis. Cardiac arrhythmias and skeletal muscle weakness are the consequences of any of these
problems, and should these deﬁcits occur in concert,
disaster awaits. Hypophosphatemia is associated in ventilator patients with a failure-to-wean.11 Phosphate transfer
during an intermittent hemodialysis session was less than
half of that occurring during a 24-hour CRRT treatment,
despite a 4-fold higher clearance with hemodialysis.12
The phosphate deﬁcit can be dispatched by using a
phosphate-containing dialysate,13 and there is no
commercially equivalent solution available in the United
States, although a pre-mixed phosphate-containing
CRRT replacement solution is available (Phoxillum,
Baxter). Alternatively, a concocted sodium/potassium
phosphate dialysate is possible. Finally, sodium glycerophosphate pentahydrate could be used, especially in the

face of a pharmacy-based phosphate supply problem.
Due to the inexperience of most practitioners directly
manipulating the dialysate, most clinicians opt to infuse
one of these solutions, but this strategy requires greater
frequency of monitoring than a ﬁxed phosphate concentration dialysate.
In addition, there may be renal trauma induced by
overly ambitious efﬂuent rates. Maynar-Molinar and colleagues14 recently coined the term, “dialytrauma,” which
more comprehensively speaks to the less well-perceived
negative effects of continuous renal replacement treatment.15 A partial listing of these traumatic events includes
the aforementioned electrolyte and mineral disturbances,
caloric loss through heat dissipation, carbohydrates, nitrogen, water-soluble vitamins, trace elements, and drugs,
particularly antibiotic agents. In this vein, Lewis and Mueller16 previously demonstrated the requirement for
greater antibiotic doses during CRRT because prevailing
antibiotic levels were lower than the threshold for a bactericidal effect. Levels were less than optimal attributable to
prolonged hemoﬁltration and other reasons, including
improved hepatic clearance in AKI patients (compared
with ESRD patients) and variability in body habitus and
ﬂuid composition of patients undergoing CRRT. Clinicians were warned against antibiotic conservatism: antibiotic dosing should be aggressively administered to
vulnerable, critically ill patients treated with CRRT. This
warning is a clarion call for greater research involving
not only antibiotics and other commonly used agents in
ICU patients. Even the pharmacokinetics and pharmacodynamics of commonly used vasopressors are not well
described during sustained low-efﬁciency daily dialysis
(SLED) or CVVH(D). Commonly used vasopressors are
dialyzable, but dose adjustments are rarely made for patients undergoing CVVH(D) or SLED. However, Honore
and colleagues15 contend that “CRRT is not a ‘hurdle’
for adequate antimicrobial dosing but rather a ‘shield’ allowing higher antimicrobial dosing at less toxicity risk.”
They state that although CRRT is a technique that promotes antimicrobial underdosing, it simultaneously facilitates the administration of higher antibiotic doses of per se
amikacin and colistin with a lesser risk for nephrotoxicity.15,17
Slavish adherence to a ﬁxed dialysis schedule for hospitalized patients potentially injures them or at best provides no beneﬁt. The excessive clearance of “uremic
solutes” has not been shown to provide superior outcomes, if one extrapolates outpatient kinetic data to inpatients.18 If a patient is not hypercatabolic and eating
minimally or not at all, and there is essentially no or minimal administration of ﬂuids, hemodialysis is not required
“per schedule” as is generally perceived and executed.
With an increasing number of inpatients undergoing
hemodialysis or CRRT, the reduction of 1 or 2 dialytic
treatments liberates personnel for greater logistical execution, that is, longer therapies where required. In addition,
there is the aberrant concept of instituting dialysis to prevent hyperkalemia at serum potassium concentrations
mildly exceeding 5 mmol/L. One must always rule out
pseudohyperkalemia. There is always the possibility
that tourniquet- and ﬁst-clenching–induced hyperkalemia
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is present, especially in patients in whom blood has been
drawn repeatedly.19 This explanation is rarely considered,
and patients are dialyzed for a venipuncturist’s diligence,
the consequence of which is removal of potassium
precious to the milieu intracellulaire. This scenario represents a misfear because the vast majority of patients do
not develop electrocardiographic changes of severe hyperkalemia with consequent arrhythmias. Two decades
ago, Allon and colleagues20 delineated the phenomenon
of “fasting hyperkalemia” for which the solution is simply
sugar, that is, carbohydrate administration, with the
foreknowledge that CKD is accompanied by insulin resistance, which may occur at earlier stages of CKD than heretofore appreciated.21,22 Because glucose and potassium
entry into cells represents 2 different pathways, one
must fully appreciate that insulin is the hypokalemiainducing agent, not glucose. Per the collective body of evidence from rubidium studies in ESRD patients, it is
probable that total potassium bodily stores are in
deﬁcit in a substantial proportion of the hemodialyzed
population.23-25 So, why remove even more potassium,
when redisplacement into cells is the correct therapeutic
maneuver, and we already know how to do that?
The Bauhaus architect, Ludwig Mies van der Rohe
(1886-1969), has been famously miscredited with stating
that “less is more.” Later, one of his admirers, an industrial designer ampliﬁed van der Rohe with “less but better.” Nephrologists who work or consult in ICUs should
take heed of both these architectural axioms. There will
be times that a rational withholding of enthusiasm will
provide gains for the critically ill patient.
Jerry Yee, MD
Editor-in-Chief
Division of Nephrology and Hypertension
Henry Ford Hospital, Detroit, MI
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